Crystal Structures And Analysis Of

1,2,4 Triazole And Pyrazole Compounds by Goh , Jia Hao



























UNIVERSITI SAINS MALAYSIA 
2011 
 























Thesis submitted in fulfillment of the requirements 
for the Degree of 







First of all, I owe my deepest gratitude to my family members who have given me 
the opportunity for postgraduate education. This thesis would not have been possible 
without their patience, understanding and spiritual support in realizing my dreams. 
I am heartily thankful to my supervisor, Professor Fun Hoong Kun, whose 
supervisions, encouragements and supports from the preliminary to the final stage 
enabled me to complete my thesis successfully. His continual and convincing spirit of 
“Crystallography is Fun and Fun is Crystallography” in concern to research as well as 
teaching had enabled me to develop a thorough understanding of X-ray Crystallography. 
Besides that, I would like to dedicate my heartfelt gratitude also to my co-supervisor, 
Associate Professor Abdul Razak Ibrahim for his untiring effort, commitment and 
guidance throughout my studies. 
In addition, I greatly thank Universiti Sains Malaysia and Institute of Postgraduate 
Studies, USM for a wide range of facilities and supports provided as well as the USM 
Fellowship awarded. Financial support provided by the Research University Golden 
Goose Grant (1001/PFIZIK/811012) and the Science Fund (305/PFIZIK/613312) are also 
acknowledged. Besides that, it is my pleasure to thank fellow researchers from India 
especially Professor B. Kalluraya and Associate Professor Arun M. Isloor, for providing 
research samples and cooperation in journal publications. 
Last but not least, I am greatly appreciative of all members of X-ray 
Crystallography Unit, School of Physics, Universiti Sains Malaysia for their kind and 
helpful cooperation throughout my research in the laboratory. 
 ii
TABLE OF CONTENTS 
 
Acknowledgement ···························································································· ii 
Table of Contents ····························································································· iii 
List of Tables ··································································································· x 
List of Figures ·································································································· xii 
List of Plates ···································································································· xvi 
Abstrak ············································································································ xvii 
Abstract ··········································································································· xix 
 
CHAPTER 1 – INTRODUCTION 
1.1 X-ray Crystallography ······································································ 1   
1.2 1,2,4-Triazole Derivatives ································································· 3  
1.2.1 Preparation of 1,2,4-Triazole Derivatives ······································· 4 
1.2.2 Applications of 1,2,4-Triazole Derivatives ····································· 5 
1.3 Pyrazole Derivatives ········································································· 7   
1.3.1 Preparation of Pyrazole Derivatives ··············································· 8 
1.3.2 Applications of Pyrazole Derivatives ············································· 8 
1.4 Research Objective ·········································································· 10   
 
CHAPTER 2 – BASIC PRINCIPLES OF X-RAY STRUCTURE ANALYSIS 
2.1 Generation of X-rays ········································································ 13  
2.1.1 X-ray Tube ················································································· 16  
2.2 Crystal Systems ················································································ 18  
2.3 X-ray Diffraction ·············································································· 21  
2.3.1 Reciprocal Lattice ······································································· 23  
2.3.2 Bragg’s Law in Reciprocal Space ················································· 24  
2.3.3 Argand Diagram ········································································· 26  
2.3.4 Combination of N waves ······························································ 28  
2.3.5 Phase Difference ········································································· 29  
2.3.6 Atomic Scattering Factors ···························································· 29  
 iii
2.3.7 Structure Factor ··········································································· 32  
2.3.8 Friedel’s Law ·············································································· 33  
2.3.9 Limiting Conditions and Systematic Absences ······························· 36  
2.4 Fourier Series ··················································································· 37  
2.4.1 Electron Density and Structure Factor ··········································· 40  
2.4.2 Electron Density Equation ··························································· 41  
2.4.3 Interpretation of Electron Density Distribution ······························· 42  
2.5 The Patterson Function ····································································· 43   
2.6 Direct Method ·················································································· 43  
2.7 Data Reduction ················································································· 47  
2.7.1 Lorentz and Polarization Corrections ············································· 47  
2.7.2 Absorption Corrections ································································ 48  
2.7.3 Extinction ·················································································· 49  
2.8 Structure Refinement ········································································ 52  
2.8.1 Least-Squares Refinement ··························································· 52  
2.8.2 Crystallographic R-values ···························································· 54  
2.8.3 Location and Treatment of Hydrogen Atoms ································· 55  
2.8.4 Residual Electron Density ···························································· 56  
2.9 Interpretation and Presentation of Results ··········································· 57  
2.9.1 Bond Lengths and Angles ···························································· 57  
2.9.2 Torsion Angle ············································································· 58  
2.9.3 Mean Planes and Interplanar Angle ·············································· 60  
2.9.4 Precision ···················································································· 60  
2.9.5 Graphical Representations ···························································· 61  
2.10 Additional Topics ············································································· 61  
2.10.1 Disorders ···················································································· 61  
2.10.1.1 Site Occupancy Disorder ·················································· 62  
2.10.1.2 Positional and Orientational Disorder ································· 62  
2.10.2 Ring Conformations ···································································· 63  
2.10.3 Limitations of X-ray Structure Analysis ········································ 65  
2.10.4 Cis-trans Isomerism ···································································· 66  
 iv
  
CHAPTER 3 – MATERIALS AND METHODS 
3.1 Introduction ····················································································· 67  
3.2 APEXII System ················································································ 67  
3.2.1 Hardware Overview ···································································· 67  
3.2.1.1 APEXII Detector ··································································· 70  
3.2.1.2 Goniometer ··········································································· 71  
3.2.1.3 X-ray Source ········································································· 72  
3.2.1.4 X-ray Generator ····································································· 72  
3.2.1.5 Timing Shutter and Collimator ················································ 73  
3.2.1.6 Video Microscope ·································································· 73  
3.2.1.7 Radiation Safety Enclosure ····················································· 74  
3.2.1.8 Refrigerated Recirculator for the Detector ································ 74  
3.2.1.9 Computers ············································································· 74  
3.2.1.10 Cobra Low-Temperature Attachment ···································· 74  
3.2.2 Software Overview ······································································ 75  
3.2.2.1 Bruker Instrument Service ······················································ 75  
3.2.2.2 APEX2 ················································································· 76  
3.3 SHELXTL Software Package ····························································· 77  
3.3.1 XPREP – Space Group Determination ··········································· 77  
3.3.2 XS – Structure Solution ································································ 77  
3.3.3 XL – Least-Squares Refinement ···················································· 77  
3.3.4 XP – Graphical Representation ····················································· 78  
3.4 Methods and Experiments ·································································· 79  
3.4.1 Choose and Mount a Crystal ························································· 80  
3.4.2 Center and Screen a Crystal ·························································· 81  
3.4.2.1 Mount the Goniometer Head ··················································· 81  
3.4.2.2 Center a Crystal ····································································· 82  
3.4.2.3 Measure the Crystal Dimension ··············································· 83  
3.4.3 Data Collection ··········································································· 83  
3.4.3.1 Create a New Directory ·························································· 83  
 v
3.4.3.2 Phi 360° Simple Scan ····························································· 83  
3.4.3.3 Determine the Unit Cell ·························································· 84  
3.4.3.4 Refine the Data Collection Strategy ········································· 86  
3.4.3.5 Collect Data/Run Experiment ·················································· 87  
3.4.4 Data Integration and Scaling ························································· 88  
3.4.4.1 Integrate Data ········································································ 88  
3.4.4.2 Monitor the SaintChart ··························································· 89  
3.4.4.3 Scale Data ············································································· 90  
3.4.5 Space Group Determination ························································· 91  
3.4.6 Structure Solution ······································································· 94  
3.4.7 Access the Solution ····································································· 94  
3.4.7.1 Edit the Instruction File ·························································· 95  
3.4.8 Least-Squares Refinement ···························································· 97  
3.4.8.1 Clean Up the Structure ··························································· 98  
3.4.8.2 Anisotropic Refinement ·························································· 99  
3.4.8.3 Refined Hydrogen Treatment ·················································· 100 
3.4.8.4 Idealized Hydrogen Treatment ················································ 101 
3.4.8.5 Absorption Correction ···························································· 102 
3.4.8.6 Weighting Schemes ································································ 103 
3.4.9 Graphical Representation ····························································· 103 
3.4.9.1 Plot an Ortep Diagram ···························································· 103 
3.4.9.2 Plot a Packing Diagram ·························································· 104 
3.5 Synthesis and Crystallization ····························································· 105 
3.5.1 Compound 1 ··············································································· 105 
3.5.2 Compound 2 ··············································································· 106 
3.5.3 Compound 3 ··············································································· 106 
3.5.4 Compound 4 ··············································································· 106 
3.5.5 Compound 5 ··············································································· 107 
3.5.6 Compound 6 ··············································································· 107 
3.5.7 Compound 7 ··············································································· 108 
3.5.8 Compound 8 ··············································································· 108 
 vi
3.5.9 Compound 9 ··············································································· 108 
3.5.10 Compound 10 ············································································· 109 
3.5.11 Compound 11 ············································································· 109 
3.5.12 Compound 12 ············································································· 110 
3.5.13 Compound 13 ············································································· 110 
3.5.14 Compound 14 ············································································· 110 
3.5.15 Compound 15 ············································································· 111 
 
CHAPTER 4 – RESULTS AND DISCUSSION 
4.1 Compound 1 ····················································································· 112 
4.1.1 Data Collection ··········································································· 113 
4.1.2 Discussion ·················································································· 114 
4.1.3 Refinement ················································································· 116 
4.2 Compound 2 ····················································································· 118 
4.2.1 Data Collection ··········································································· 119 
4.2.2 Discussion ·················································································· 120  
4.2.3 Refinement ················································································· 123 
4.3 Compound 3 ····················································································· 125 
4.3.1 Data Collection ··········································································· 126 
4.3.2 Discussion ·················································································· 127 
4.3.3 Refinement ················································································· 132 
4.4 Compound 4 ····················································································· 133 
4.4.1 Data Collection ··········································································· 134 
4.4.2 Discussion ·················································································· 135 
4.4.3 Refinement ················································································· 138 
4.5 Compound 5 ····················································································· 139 
4.5.1 Data Collection ··········································································· 140 
4.5.2 Discussion ·················································································· 141 
4.5.3 Refinement ················································································· 144 
4.6 Compound 6 ····················································································· 145  
4.6.1 Data Collection ··········································································· 146 
 vii
4.6.2 Discussion ·················································································· 147 
4.6.3 Refinement ················································································· 150 
4.7 Compound 7 ····················································································· 151 
4.7.1 Data Collection ··········································································· 152 
4.7.2 Discussion ·················································································· 153 
4.7.3 Refinement ················································································· 157 
4.8 Compound 8 ····················································································· 158 
4.8.1 Data Collection ··········································································· 159 
4.8.2 Discussion ·················································································· 160 
4.8.3 Refinement ················································································· 164 
4.9 Compound 9 ····················································································· 165 
4.9.1 Data Collection ··········································································· 166 
4.9.2 Discussion ·················································································· 167 
4.9.3 Refinement ················································································· 171 
4.10 Compound 10 ··················································································· 172 
4.10.1 Data Collection ··········································································· 173 
4.10.2 Discussion ·················································································· 174 
4.10.3 Refinement ················································································· 177 
4.11 Compound 11 ··················································································· 179 
4.11.1 Data Collection ··········································································· 180 
4.11.2 Discussion ·················································································· 181 
4.11.3 Refinement ················································································· 184  
4.12 Compound 12 ··················································································· 186 
4.12.1 Data Collection ··········································································· 187 
4.12.2 Discussion ·················································································· 188 
4.12.3 Refinement ················································································· 191 
4.13 Compound 13 ··················································································· 193 
4.13.1 Data Collection ··········································································· 194 
4.13.2 Discussion ·················································································· 195 
4.13.3 Refinement ················································································· 199 
4.14 Compound 14 ··················································································· 200 
 viii
4.14.1 Data Collection ··········································································· 201 
4.14.2 Discussion ·················································································· 202 
4.14.3 Refinement ················································································· 206 
4.15 Compound 15 ··················································································· 207 
4.15.1 Data Collection ··········································································· 208 
4.15.2 Discussion ·················································································· 209 
4.15.3 Refinement ················································································· 213 
 
CHAPTER 5 – SUMMARY AND CONCLUSION 
5.1 1,2,4-Triazole Derivatives ································································· 215 
5.1.1 Compounds Possessing 4,5-Dihydro-1H-1,2,4-triazole Moiety ········ 215 
5.1.2 Compounds Possessing 4H-1,2,4-Triazole Moiety ·························· 217 
5.2 Pyrazole Derivatives ········································································· 218 
5.2.1 Compound Possessing 2,5-Dihydro-1H-pyrazole Moiety ················ 218 
5.2.2 Compound Possessing 4,5-Dihydro-1H-pyrazole Moiety ················ 219 
5.2.3 Compounds Possessing 1H-Pyrazole Moiety ·································· 220 
5.3 Recommendation for Future Research ················································· 222 
 
REFERENCES ································································································· 223 
APPENDIXES 
LIST OF PUBLICATIONS 
 ix
LIST OF TABLES 
 
 Page 
Table 2.1 The seven crystal systems ·························································· 19  
Table 2.2 The 14 Bravais lattices ······························································ 20  
Table 2.3 Limiting conditions for unit cell type ·········································· 36  
Table 2.4 Limiting conditions for common screw axes ······························· 37  
Table 2.5 Limiting condition for glide planes ············································ 37  
Table 2.6  Cis- and trans-1,2-dichloroethene ·············································· 66  
 
Table 4.1 Crystal data of Compound 1 ····················································· 113  
Table 4.2 Hydrogen bond geometry of Compound 1 ································· 116 
Table 4.3 Crystal data of Compound 2 ····················································· 119 
Table 4.4 Hydrogen bond geometry of Compound 2 ································· 122 
Table 4.5 Crystal data of Compound 3 ····················································· 126 
Table 4.6 Hydrogen bond geometry of Compound 3 ································· 131 
Table 4.7 Crystal data of Compound 4 ····················································· 134 
Table 4.8 Hydrogen bond geometry of Compound 4 ································· 137 
Table 4.9 Crystal data of Compound 5 ····················································· 140 
Table 4.10 Hydrogen bond geometry of Compound 5 ································· 143 
Table 4.11  Crystal data of Compound 6 ····················································· 146 
Table 4.12 Hydrogen bond geometry of Compound 6 ································· 149 
Table 4.13 Crystal data of Compound 7 ····················································· 152 
Table 4.14 Hydrogen bond geometry of Compound 7 ································· 156 
Table 4.15 Crystal data of Compound 8 ····················································· 159 
Table 4.16 Hydrogen bond geometry of Compound 8 ································· 163 
Table 4.17 Crystal data of Compound 9 ····················································· 166 
Table 4.18 Hydrogen bond geometry of Compound 9 ································· 171 
Table 4.19 Crystal data of Compound 10 ··················································· 173 
Table 4.20 Hydrogen bond geometry of Compound 10 ······························· 177 
Table 4.21 Crystal data of Compound 11 ··················································· 180 
 x
Table 4.22 Hydrogen bond geometry of Compound 11 ······························· 184 
Table 4.23 Crystal data of Compound 12 ··················································· 187 
Table 4.24 Hydrogen bond geometry of Compound 12 ······························· 191 
Table 4.25 Crystal data of Compound 13 ··················································· 194 
Table 4.26 Hydrogen bond geometry of Compound 13 ······························· 199 
Table 4.27 Crystal data of Compound 14 ··················································· 201 
Table 4.28 Hydrogen bond geometry of Compound 14 ······························· 206 
Table 4.29 Crystal data of Compound 15 ··················································· 208 
Table 4.30 Hydrogen bond geometry of Compound 15 ······························· 213 
 
Table 5.1 Comparison of bond lengths of 4,5-dihydro-1H-1,2,4-triazole 
 moiety of Compounds 1, 2, 3, 4 and 5 ········································ 216 
Table 5.2 Comparison of angles of 4,5-dihydro-1H-1,2,4-triazole moiety 
 of Compounds 1, 2, 3, 4 and 5 ·················································· 216 
Table 5.3 Comparison of bond lengths of 4H-1,2,4-triazole moiety of 
Compounds 6, 7, 8 and 9 ·························································· 218 
Table 5.4 Comparison of angles of 4H-1,2,4-triazole moiety of  
 Compounds 6, 7, 8 and 9 ·························································· 218 
Table 5.5 Bond lengths of 2,5-dihydro-1H-pyrazole moiety of 
 Compound 10 ········································································· 219 
Table 5.6 Angles of 2,5-dihydro-1H-pyrazole moiety of 
 Compound 10 ········································································· 219 
Table 5.7 Bond lengths of 4,5-dihydro-1H-pyrazole moiety of 
 Compound 11 ·········································································  220 
Table 5.8 Angles of 4,5-dihydro-1H-pyrazole moiety of 
 Compound 11 ········································································· 220 
Table 5.9 Comparison of bond lengths of 1H-pyrazole moiety of 
Compounds 12, 13, 14 and 15 ·················································· 221 
Table 5.10 Comparison of angles of 1H-pyrazole moiety of  
 Compounds 12, 13, 14 and 15 ·················································· 221 
 xi
LIST OF FIGURES 
 
 Page 
Figure 1.1 Schematic diagram of 1,2,4-triazole ··········································· 3 
Figure 1.2 Einhorn-Brunner reaction scheme ·············································· 4 
Figure 1.3 Pellizzari reaction scheme ························································· 5 
Figure 1.4 Schematic structure of fluconazole, containing two 1,2,4-triazole 
 moieties ··················································································· 5 
Figure 1.5 Schematic structure of itraconazole, containing two 1,2,4-triazole 
 moieties ··················································································· 5 
Figure 1.6 Schematic diagram of pyrazole ·················································· 7 
Figure 1.7 Pyrazole derivatives reaction scheme ·········································· 8 
Figure 1.8 Schematic structure of Celecoxib, containing a pyrazole moiety ···· 9 
Figure 1.9 Schematic structure of Metamizole sodium, containing a 
 pyrazole moiety ········································································· 9 
 
Figure 2.1 Continuous X-ray spectra as a function of accelerating voltage ····· 13 
Figure 2.2 X-ray Spectra with characteristic peaks ······································· 14 
Figure 2.3 Cross-sectional schematic of a sealed filament X-ray tube ············ 16 
Figure 2.4 Unit Cell ·················································································· 18 
Figure 2.5 Construction showing conditions for diffraction ·························· 21 
Figure 2.6 Diffraction in terms of the reciprocal lattice ································ 24 
Figure 2.7 Sections through the sphere of reflection and the limiting sphere ·· 25 
Figure 2.8 Combination of two waves,  and  as vectors on 11
φief 22
φief
 an Argand diagram ··································································· 27 
Figure 2.9 Combination of N waves (N = 6) on an Argand diagram ·············· 28 
Figure 2.10 Atomic scattering factor ··························································· 30 
Figure 2.11 Structure factor  plotted on an Argand diagram ················ 32 )(hklF
Figure 2.12 Relationship between  and )(hklF )( lkhF  ·································· 35 
Figure 2.13 One-dimensional periodic function, of repeat a ··························· 37 
 xii
Figure 2.14 Illustration of primary extinction ················································ 49 
Figure 2.15 Mosaic structure of a real crystal ················································ 50 
Figure 2.16 Geometry of the calculation of interactomic distances and angles ·· 57 
Figure 2.17 Torsion angle )4,3,2,1(χ  ··························································· 59 
Figure 2.18 Commonly observed conformations of six-membered rings ········· 64 
 xiii
Figure 3.1  Schematic diagram of the APEXII system ·································· 70 
Figure 3.2 SMART APEXII goniometer components ·································· 71 
Figure 3.3 Main window of APEX2 program ············································· 76 
Figure 3.4 Flow chart of solving a structure ·············································· 79
Figure 3.5 Goniometer head ····································································· 81 
Figure 3.6 The SaintChart ········································································ 89 
Figure 3.7 Main window of XPREP program ············································· 91 
Figure 3.8 Ten cycles of lease-square refinement ········································ 97  
 
Figure 4.1 Schematic diagram of Compound 1 ·········································· 112 
Figure 4.2 Molecular structure of Compound 1 ········································· 114 
Figure 4.3 Crystal packing of Compound 1 ··············································· 115 
Figure 4.4 Schematic diagram of Compound 2 ·········································· 118 
Figure 4.5 Molecular structure of Compound 2 ·········································· 120 
Figure 4.6 Crystal packing of Compound 2 ··············································· 122 
Figure 4.7 Schematic diagram of Compound 3 ·········································· 125 
Figure 4.8 Molecular structure of Compound 3 ········································· 127 
Figure 4.9 Superposition of molecule B (solid lines) on molecule A 
 (dashed lines) ··········································································· 129 
Figure 4.10 Crystal packing of Compound 3 ··············································· 130 
Figure 4.11 Schematic diagram of Compound 4 ·········································· 133 
Figure 4.12 Molecular structure of Compound 4 ········································· 135 
Figure 4.13 Crystal packing of Compound 4 ··············································· 137 
Figure 4.14 Schematic diagram of Compound 5 ·········································· 139 
Figure 4.15 Molecular structure of Compound 5 ·········································· 141 
Figure 4.16 Crystal packing of Compound 5 ················································ 143 
Figure 4.17 Schematic diagram of Compound 6 ··········································· 145 
Figure 4.18 Molecular structure of Compound 6 ·········································· 147 
Figure 4.19 Crystal packing of Compound 6 ················································ 149 
Figure 4.20 Schematic diagram of Compound 7 ··········································· 151 
Figure 4.21 Molecular structure of Compound 7 ·········································· 153 
 xiv
Figure 4.22 Superposition of Compound 7 (solid lines) on Compound 6 
 (dashed lines) ··········································································· 155 
Figure 4.23 Crystal packing of Compound 7 ··············································· 156 
Figure 4.24 Schematic diagram of Compound 8 ··········································· 158 
Figure 4.25 Molecular structure of Compound 8 ·········································· 160 
Figure 4.26 Superposition of Compound 8 (solid lines) on Compound 6 
 (dashed lines) ··········································································· 162 
Figure 4.27 Crystal packing of Compound 8 ················································ 163 
Figure 4.28 Schematic diagram of Compound 9 ··········································· 165 
Figure 4.29 Molecular structure of Compound 9 ·········································· 167 
Figure 4.30 Superposition of Compound 9 (solid lines) on Compound 6 
 (dashed lines) ··········································································· 169 
Figure 4.31 Crystal packing of Compound 9 ················································ 170 
Figure 4.32 Schematic diagram of Compound 10 ········································· 172 
Figure 4.33 Molecular structure of Compound 10 ········································ 174 
Figure 4.34 Crystal packing of Compound 10 ·············································· 176 
Figure 4.35 Schematic diagram of Compound 11 ········································· 179 
Figure 4.36 Molecular structure of Compound 11 ········································ 181 
Figure 4.37 Crystal packing of Compound 11 ·············································· 183 
Figure 4.38 Schematic diagram of Compound 12 ········································· 186 
Figure 4.39 Molecular structure of Compound 12 ········································ 188 
Figure 4.40 Crystal packing of Compound 12 ·············································· 190 
Figure 4.41 Schematic diagram of Compound 13 ········································· 193 
Figure 4.42 Molecular structure of Compound 13 ········································ 195 
Figure 4.43 Superposition of Compound 13 (solid lines) on Compound 12 
 (dashed lines) ··········································································· 197 
Figure 4.44 Crystal packing of Compound 13 ·············································· 198 
Figure 4.45 Schematic diagram of Compound 14 ········································· 200 
Figure 4.46 Molecular structure of Compound 14 ········································ 202 
Figure 4.47 Superposition of Compound 14 (solid lines) on Compound 12 
 (dashed lines) ··········································································· 204 
 xv
Figure 4.48 Crystal packing of Compound 14 ·············································· 205 
Figure 4.49 Schematic diagram of Compound 15 ········································· 207 
Figure 4.50 Molecular structure of Compound 15 ········································ 209 
Figure 4.51 Superposition of Compound 15 (solid lines) on Compound 12 
 (dashed lines) ··········································································· 211 
Figure 4.52 Crystal packing of Compound 15 ·············································· 212 
 
Figure 5.1 Schematic diagram of 4,5-dihydro-1H-1,2,4-triazole moiety ········· 216 
Figure 5.2 Schematic diagram of 4H-1,2,4-triazole moiety ··························· 217 
Figure 5.3 Schematic diagram of 2,5-dihydro-1H-pyrazole moiety ··············· 219 
Figure 5.4 Schematic diagram of 4,5-dihydro-1H-pyrazole moiety ················ 220 
Figure 5.5 Schematic diagram of 1H-pyrazole moiety ·································· 221 
 xvi
LIST OF PLATES 
 
 Page 
Plate 3.1 The Bruker SMART APEXII CCD diffractometer 
 in X-ray Crystallography Unit, School of Physics, USM ·············· 68 
Plate 3.2 The Bruker APEXII DUO CCD diffractometer 
 in X-ray Crystallography Unit, School of Physics, USM ·············· 69 
 
 xvii
STRUKTUR-STRUKTUR HABLUR DAN ANALISIS-ANALISIS 




Penyelidikan ini adalah bertujuan untuk mengkaji struktur-struktur hablur bagi 
sebatian-sebatian 1,2,4-triazol dan pirazol yang berperanan penting dalam aspek biologi 
dan farmakologi dengan kaedah kristalografi sinar-X hablur tunggal. Satu siri yang terdiri 
daripada sembilan sebatian bagi terbitan 1,2,4-triazol dan satu siri yang terdiri daripada 
enam sebatian bagi terbitan pyrazol disintesis dan dihablur untuk mendapatkan hablur 
tunggal. Data dikumpul dengan menggunakan diffraktometer-diffraktometer CCD Bruker 
SMART APEXII atau Bruker APEXII DUO. Struktur diselesaikan dengan kaedah terus 
dan disempurnakan dengan kaedah kuasa-dua terkecil. Parameter-parameter geometri dan 
penyusunan hablur diperoleh dan akhirnya perbandingan mudah telah dilakukan untuk 
beberapa struktur yang berkaitan. Keputusan kajian menunjukkan lapan daripada sebatian 
tersebut telah menghablur dalam kumpulan ruang monoklinik , lima dalam 
kumpulan ruang triklinik 
cP /21
1P  manakala dua lagi dalam kumpulan ruang monoklinik 
. Parameter-parameter geometri yang diperhati adalah dalam julat normal dan 
adalah konsisten dengan yang diperhati dalam struktur-struktur yang berkaitan. Tiada 
ikatan hidrogen antara molekul diperhati untuk dua sebatian manakala sebatian-sebatian 
yang lain membentuk ikatan hidrogen antara molekul dalam struktur hablur. Interaksi 
lemah antara molekul juga dapat diperhati dalam beberapa sebatian tersebut. Sebagai 
perbandingan, walaupun beberapa struktur yang berkaitan dihablur dalam kumpulan 
cC /2
 xviii
ruang yang berbeza, struktur-struktur hablur tersebut adalah berpadanan dan mempunyai 
persamaan dalam geometri molecular. 
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CRYSTAL STRUCTURES AND ANALYSIS 




The purpose of this research is to study the crystal structures of some biologically 
and pharmacologically important 1,2,4-triazole and pyrazole compounds by single crystal 
X-ray crystallography method. A series of nine compounds of 1,2,4-triazole derivatives 
and a series of six compounds of pyrazole derivatives were synthesized and crystallized 
to obtain single crystals. The data was collected using either Bruker SMART APEXII or 
Bruker APEXII DUO CCD area-detector diffractometers. The structures were solved by 
direct methods and refined by least-squares method. The geometrical parameters as well 
as crystal packing were obtained and finally simple comparisons were undertaken for 
some closely related structures. Results showed that eight of the compounds crystallized 
in the monoclinic space group , five in the triclinic space group cP /21 1P  and the 
remaining two in the monoclinic space group . The geometrical parameters 
observed are within normal ranges and consistent to those observed in related structures. 
No intermolecular hydrogen bond is observed for two compounds whereas the remaining 
compounds form hydrogen-bonded crystal structures. Weak intermolecular interactions 
are also observed in some of these compounds. For comparison, although some closely 
related structures crystallized in different space groups, they are having closely similar 






CHAPTER 1 – INTRODUCTION 
 
 In this thesis, a series of nine compounds of 1,2,4-triazole derivatives 
(Compounds 1, 2, 3, 4, 5, 6, 7, 8 and 9) and a series of six compounds of pyrazole 
derivatives  (Compounds 10, 11, 12, 13, 14 and 15) were determined and analyzed by 
single crystal X-ray analysis method. The crystal samples were synthesized and 
crystallized by fellow researchers from Department of Studies in Chemistry, Mangalore 
University, Mangalagangotri, Mangalore, India and Department of Chemistry, National 
Institute of Technology-Karnataka, Surathkal, Mangalore, India. 
 All the crystal data were collected using either Bruker SMART APEXII or Bruker 
APEXII DUO CCD area-detector diffractometers (Bruker, 2009) at X-ray 
Crystallography Unit, School of Physics, Universiti Sains Malaysia (USM), Penang, 
Malaysia. The experimental results obtained were analyzed and have been published in 
Acta Crystallographica Section E: Structure Reports Online. 
 In this chapter, brief introductions of X-ray crystallography, general backgrounds 
and applications of 1,2,4-triazole and pyrazole derivatives as well as the research 
objective are presented. Basic principles of X-rays structure analysis are discussed in 
details in the next chapter. 
 
1.1 X-ray Crystallography 
X-ray crystallography is an analytical technique in which X-ray diffraction 
methods are employed to determine the actual three-dimensional arrangement of atoms in 
a crystalline structure. The science of X-ray crystallography originated with the discovery 
by Max von Laue in 1912 that crystals diffract X-ray radiations. Since then, single crystal 
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X-ray crystallography has developed into the most powerful method for obtaining the 
atomic arrangement in crystalline state. 
 Structure analysis by X-ray crystallography can be applied to a wide range of 
structure sizes, from small organic molecules and simple salts, to complex minerals, 
synthetically prepared inorganic and organo-metallic complexes, natural product 
compounds as well as to biological macromolecules, such as proteins and viruses. 
 The precise information of molecular geometry is important in nearly all fields of 
chemical and biological researches. The three-dimensional atomic coordinates can be 
easily obtained from the comprehensive crystallographic databases such as the 
Cambridge Structural Database (CSD) and Protein Data Bank. Crystallographic analyses 
are always the starting point for molecular modeling as well as drug design. In fact, many 
of most significant advances in structural chemistry and structural biology are based upon 
X-ray crystallography analyses. 
 Generally, the results obtained from X-ray crystallography analyses are 
complementary to other commonly used solid-state techniques such as X-ray powder 
diffraction, solid-state NMR, EPR, FT-IR and Raman spectroscopy, and neutron 
diffraction. Chemists also routinely use such techniques as nuclear magnetic resonance, 
infrared and ultraviolet spectroscopy, mass spectrometry, x-ray fluorescence, and 
elemental analysis for the identification and characterization of compounds prepared. 
After suitable analysis and interpretation, the experimental results obtained from these 
techniques may yield important information concerning the composition and structure of 
the compound. However, such information is always incomplete, fragmentary and 
ambiguous. There are a number of classes of chemical compounds such as natural 
product compounds, organo-metallic complexes, inorganic salts, metal cluster systems, 
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organic and inorganic reaction products for which the complete structure cannot be 
deduced even with all of the other methods combined. X-ray crystallography is uniquely 
capable of unambiguously determining the complete three-dimensional molecular 
structures (including the absolute stereochemistry) of chemical substances. 
 
 
1.2 1,2,4-Triazole Derivatives 
 
 
Figure 1.1 Schematic diagram of 1,2,4-triazole 
 
 1,2,4-Triazole [systematic name: 1H-1,2,4-triazole], with molecular formula 
C2H3N3, is one of a class of simple organic heterocyclic compounds containing a five-
membered ring composed of three nitrogen atoms and two carbon atoms at non-adjacent 
positions. A degree of respectability has been bestowed upon 1,2,4-triazole derivatives 
due to their various pharmacological activities such as analgesic (Amir & Shikha, 2004), 
anti-helminthic (Holla et al., 2003), anti-oxidant (Kuş et al., 2008), anti-tuberculosis 
(Walczak et al., 2004), anti-cancer (Bekircan & Bektas, 2006; Sztanke et al., 2008), anti-
convulsant (Almasirad et al., 2004; Bekircan & Bektas, 2006), anti-fungal (Amir et al., 
2008; Bekircan & Bektas, 2006; Holla et al., 2003), anti-bacterial (Amir et al., 2008; 
Bekircan & Bektas, 2006; Holla et al., 2003), anti-microbial (Demirbas et al., 2004; 
Sztanke et al., 2008; Turan-Zitouni et al., 2005), anti-tumor (Al-Soud et al., 2003; Amir 
et al., 2008; Demirbas et al., 2004) and anti-inflammatory (Amir & Shikha, 2004; Amir 
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et al., 2008; Bekircan & Bektas, 2006; Sujith et al., 2009). They also act as effective 
pesticides (Koparır et al., 2005). Some of the present day drugs such as Ribavirin (anti-
viral agent), Rizatriptan (anti-migraine agent), Alprazolam (anxiolytic agent), 
Fluconazole and Itraconazole (anti-fungal agents) are the best examples of potent 
molecules possessing the triazole nucleus (Fun et al., 2009). Furthermore, the amino and 
mercapto groups of thio-substituted 1,2,4-triazole serve as readily accessible nucleophilic 
centers for the preparation of N-bridged heterocycles. 
 
1.2.1 Preparation of 1,2,4-Triazole Derivatives 
 1,2,4-Triazole derivatives can be prepared using the Einhorn-Brunner reaction or 
Pellizzari reaction (1,2,4-Triazole, 2011). 
 
Einhorn-Brunner Reaction: 
The chemical reaction of imides with alkyl hydrazines to form a mixture of 
isomeric 1,2,4-triazole (Einhorn-Brunner reaction, 2011). 
 
 









Figure 1.3 Pellizzari reaction scheme 
 
1.2.2 Applications of 1,2,4-Triazole Derivatives 
 1,2,4-Triazole derivatives find use in a wide variety of applications, most notably 





Figure 1.4 Schematic structure of fluconazole, containing two 1,2,4-triazole moieties 
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Fluconazole is used in the treatment and prevention of superficial and systemic 
fungal infections. It is commonly marketed under the trade name of Diflucan® or 





Figure 1.5 Schematic structure of itraconazole, containing two 1,2,4-triazole moieties  
 
Itraconazole is a triazole anti-fungal agent that is prescribed to patients with 
fungal infections. It is invented in 1984, marketed as Sporanox® by Janssen 





1.3 Pyrazole Derivatives 
 
 
Figure 1.6 Schematic diagram of pyrazole 
 
 Pyrazole [systematic name: 1H-pyrazole], with molecular formula C3H4N2, is one 
of a class of simple organic heterocyclic compounds containing a five-membered ring 
composed of three carbon atoms and two nitrogen atoms in adjacent positions. Pyrazole 
derivatives are in general well-known nitrogen-containing heterocyclic compounds and 
various procedures have been developed for their synthesis. The 1,3-dipolar 
cycloaddition reaction with various dipolarphiles offers a convenient synthetic route for 
the preparation of pyrazole derivatives and been studied extensively (Rai et al., 2008). 
The chemistry of pyrazole derivatives has been the subject of much interest due to their 
importance for various applications, and their widespread potential and proven biological 
and pharmacological activities such as analgesic (Tawab et al., 1960), herbicidal (Rai et 
al., 2008), tranquilizing (Rai et al., 2008), anti-tumor (Rai et al., 2008), anti-pyretic (Rai 
et al., 2008, Tawab et al., 1960), anti-inflammatory (Rathish et al., 2009), anti-cancer 
(Sridhar & Perumal, 2003), anti-malarial (Sridhar & Perumal, 2003) and anti-
hyperglycemic (Sridhar & Perumal, 2003) activities. Some alkyl- and aryl-substituted 
pyrazoles have a sharply pronounced sedative action on the central nervous system 
(Sridhar & Perumal, 2003). Certain alkyl pyrazoles also show significant bacteriostatic, 
bacteriocidal, fungicidal, analgesic and anti-pyretic activities (Sridhar & Perumal, 2003). 
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1.3.1 Preparation of Pyrazole Derivatives 
Pyrazoles are produced synthetically through the reaction of α,β-unsaturated 
aldehydes with hydrazine and subsequent dehydrogenation (Pyrazole, 2011). 
 
 
Figure 1.7 Pyrazole derivatives reaction scheme 
 
1.3.2 Applications of Pyrazole Derivatives 
 Pyrazole derivatives are widely used as analgesic, anti-inflammatory, anti-pyretic, 
tranquilizing, anti-diabetic and anti-bacterial activities. Celecoxib and Metamizole 






Figure 1.8 Schematic structure of Celecoxib, containing a pyrazole moiety 
 
Celecoxib is a sulfa non-steroidal anti-inflammatory drug (NSAID) used in the 
treatment of osteoarthritis, rheumatoid arthritis, acute pain and menstrual pain. It is 





Figure 1.9 Schematic structure of Metamizole sodium, containing a pyrazole moiety 
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 Metamizole sodium or dipyrone is a powerful analgesic and anti-pyretic drug. 
From a randomized, multinational study involving 555 children showed that metamizole 
sodium produced a significant greater body temperature reduction than ibuprofen and 
paracetamol, and it helped to maintain low body temperature for a longer duration. It is 
marketed in 1920, under various trade names including Algozone®, Algocalmin®, 
Analgin® and Dipirona®. It remained available worldwide until the 1970s, when it was 
discovered that the drug carries a small risk of causing agranulocytosis, which is lowering 
white blood cell amount. Several national medical authorities have banned it either totally 
or have restricted it to be available only on prescription (Metamizole, 2011). 
 
 
1.4 Research Objective 
 Due to the proven biological and pharmacological importance of 1,2,4-triazole 
and pyrazole heterocyclic compounds, the main research objective is to determine and 
analyze the crystal structures of some unreported 1,2,4-triazole and pyrazole compounds. 
By using the single crystal X-ray structure analysis, complete set of crystal data of these 
previously unreported structures can be obtained. All geometric parameters in the 
molecular structure such as fractional atomic coordinates, bond lengths and angles as 
well as the three-dimensional crystal packing can also be elucidated. 
(a) The X-ray structure analysis of Compound 1 {4-amino-3-(p-tolyloxymethyl)-1H-
1,2,4-triazole-5(4H)-thione} was undertaken to study the biological importance of 
the 1,2,4-triazole derivatives. 
(b) The X-ray structure analysis of Compound 2 {(E)-3-methyl-4-[(2-oxidoquinolin-
1-ium-3-yl)methyleneamino]-1H-1,2,4-triazole-5(4H)-thione N,N-dimethyl-




1-(morpholinomethyl)-1H-1,2,4-triazole-5(4H)-thione methanol hemisolvate} and 
Compound 5 {(E)-1-[(diphenylamino)methyl]-4-(4-fluorobenzylideneamino)-3-
[1-(4-isobutylphenyl)ethyl]-1H-1,2,4-triazole-5(4H)-thione} were undertaken as 
part of ongoing research on Schiff base derivatives of 1,2,4-triazole and Mannich 
bases. 
(c) The X-ray structure analysis of Compound 6 {4-[3-(phenoxymethyl)-7H-1,2,4-
triazolo[3,4-b][1,3,4]thiadiazin-6-yl]-3-(p-tolyl)sydnone}, Compound 7 {3-
phenyl-4-{3-[(p-tolyloxy)methyl]-7H-1,2,4-triazolo[3,4-b][1,3,4]thiadiazin-6-yl]-
sydnone}, Compound 8 {4-{3-[(2-isopropyl-5-methylphenoxy)methyl]-7H-
1,2,4-triazolo[3,4-b][1,3,4]thiadiazin-6-yl]-3-(p-tolyl)sydnone}, Compound 9 {4-
[3-(1-naphthyloxymethyl)-7H-1,2,4-triazolo[3,4,b][1,3,4]thiadiazin-6-yl]-3-p-
tolylsydnone} and Compound 10 {3-(2,3-dimethyl-5-oxo-1-phenyl-2,5-dihydro-
1H-pyrazole-4-yl)sydnone} were undertaken as part of ongoing research on 1,2,4-
triazole and pyrazole derivatives of sydnone nucleus. 
(d) The X-ray structure analysis of Compound 11 {5-bromo-2-[5-(4-nitrophenyl)-3-
phenyl-4,5-dihydro-1H-pyrazol-1-yl]pyrimidine} was undertaken to study the 
biological importance of the pyrazole derivatives. 
(e) The X-ray structure analysis of Compound 12 {[3-(5-nitro-2-furyl)-1-phenyl-1H-
pyrazol-4-yl](phenyl)methanone}, Compound 13 {(4-methylphenyl)[3-(5-nitro-




pyrazol-4-yl]methanone} were undertaken as part of ongoing studies on synthetic 




CHAPTER 2 – BASIC PRINCIPLES OF 
X-RAY STRUCTURE ANALYSIS 
 
 
2.1 Generation of X-rays 
 X-rays, first discovered by Wilhelm Conrad Roentgen in 1892, are 
electromagnetic radiations with wavelength, λ  in the range of 1001.0 << λ  Å. 
Continuous X-rays are produced when high speed electrons hit a target material and are 
rapidly decelerated. The minimum wavelength of these continuous X-rays obtained is 
given by 
λ
hceVE ==          (2.1)  
 
eV
hc=minλ          (2.2) 
where h  = Planck’s constant = sJ ⋅× −3410626.6  
 c   = speed of light = 1810998.2 −× ms  
 e   = electron charge = C1910602.1 −×   
 V  = accelerating voltage 
 
 
Figure 2.1 Continuous X-ray spectra as a function of accelerating voltage 
(Stout & Jensen, 1968) 
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 The maximum intensity of the X-ray spectra occurs at longer wavelength. As the 
accelerating voltage is increased, not only peak intensity and minimum wavelength are 
moved to shorter, more penetrating wavelengths, but also the total intensity is increased 
even though the electron current remains the same (Figure 2.1). 
 
 
Figure 2.2 X-ray Spectra with characteristic peaks: Mo αK  at 50 kV; 
Cu αK  at 35 kV (Stout & Jensen, 1968) 
 
 The distribution of intensity is primarily dependent on the accelerating voltage 
and only to a smaller extent of the target material. In addition, X-ray spectra show a 
number of sharp peaks of high intensity whose positions change from one material to 
another (Figure 2.2). These peaks are characteristic lines for the element of the target 
material. When the electrons bombarding the target reach the threshold potentials, they 
are capable of knocking electrons out of their innermost atomic orbitals. At a certain 
energy value, they can remove electrons from the innermost shell (K shell). This causes a 
vacancy in the K shell and it is filled by the descent of an electron from the higher shells 
(L or M shells). The difference in potential energy from the higher to the lower level 
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appears as radiation. A nearly monochromatic transition line is given out as the energy 
levels of the shells are well defined. The principal peaks are given as 
 21, αα KK  KL →  
 21, ββ KK  KM →  
 The characteristic lines shift to shorter wavelength as the atomic number, Z of the 
target material increases. In principle, almost any desired value for the αK  line can be 
obtained by selecting an appropriate target material. 
 For X-ray diffraction analysis, the radiation used should be as nearly 
monochromatic as possible. The αK  lines fulfill this requirement, but the presence of the 
accompanying βK  lines is a nuisance. To overcome this, crystal monochromator can be 
used to remove the βK  line (Stout & Jensen, 1968).  
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2.1.1 X-ray Tube 
 
Figure 2.3 Cross-sectional schematic of a sealed filament X-ray tube (Cullity, 1967) 
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 The internal construction of a sealed filament X-ray tube is shown in Figure 2.3. It 
consists of an evacuated glass envelope which insulates the anode at one end from the 
cathode at the other end. One lead of the high-voltage transformer (normally 30 to 50 kV 
for X-ray diffraction work) is connected to the filament and the other is grounded. The 
target anode is being grounded by its own water cooling system. Electrons emitted by the 
heated tungsten filament being rapidly accelerated to the target anode by the high voltage 
across the tube. The focusing cup, which is a small metal cup surrounding the heated 
filament, repels the electrons and focuses them into a narrow region of the target, so-
called the focal spot. X-ray radiations are emitted from the focal spot in all directions and 
leave the tube through two or more windows which are normally made of beryllium. 
 The conversion of incident energy of the electron beam into X-rays is a very 
inefficient process. Less than 1 % of incident energy is converted into X-ray radiations, 
the remaining heat energy is dissipated by the water cooling system. The most important 
properties of deciding an X-ray tube is the choice of the target material and the radiation 
filter. For single crystal diffraction work, Mo and Cu tubes are adequate for 99 % of all 
problems. The size and shape of the focal spot and the power are important as well since 
the X-ray intensity depends on these two parameters. Within limits, the size of the focal 
spot should be as small as possible in order to concentrate the electron energy into a small 
area of the target and hence produce a high-intensity beam of X-rays. The maximum 
power rating is the limit of amount of heat that can be dissipated by the target without 
damage to the X-ray tube (Cullity, 1967). 
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2.2 Crystal Systems 
  
 
Figure 2.4 Unit Cell 
 
 There are seven three-dimensional coordinate systems which are useful in 
describing crystals and they are the basis for the classification. Generally, a unit cell is 
characterized by six parameters, i.e. the three axial lengths (a, b and c) and three inter-
axial angles (α, β and γ) (Figure 2.4). By giving special values to these parameters, we 
can produce unit cells of various shapes and therefore various types of point lattices. It 
turns out that only seven different types of cells are necessary to include all the possible 
point lattices. These correspond to the seven crystal systems into which all crystals can be 
classified and they are listed in Table 2.1. 
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Table 2.1 The seven crystal systems (Stout & Jensen, 1967) 
Crystal system No. of independent Parameters Lattice  
 Parameters symmetry
 
Triclinic 6 cba ≠≠ ; γβα ≠≠  1  
Monoclinic 4 cba ≠≠ ; °≠°== 90;90 βγα  
m
2  
Orthorhombic 3 cba ≠≠ ; °=== 90γβα  mmm  
Tetragonal 2 cba ≠= ; °=== 90γβα  mm
m
4  
Rhombohedral 2 cba == ; °≠== 90γβα  m3  
Hexagonal 2 cba ≠= ; °=°== 120;90 γβα  mm
m
6  
Cubic 1 cba == ; α = β = γ = 90˚ mm3  
 
 Different primitive point lattices can simply be obtained by putting points at the 
corners of the unit cell of the seven crystal systems. However, there are other 
arrangements of points (non-primitive lattices) which fulfill the requirements of a point 
lattice, namely, that each point has identical surroundings. In 1848, Bravais demonstrated 
that there are a total of 14 possible point lattices and no more and thus they are called as 
the Bravais lattices. These 14 Bravais lattices consist of seven primitive and seven non-






Table 2.2 The 14 Bravais lattices (Cullity, 1967) 




Monoclinic Primitive End-centered 
  
Orthorhombic Primitive End-centered Body-centered Face-centered 
    






Simple cubic Primitive Body-centered Face-centered 
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2.3 X-ray Diffraction 
 Although X-rays had been discovered by Roentgen in 1895, but their nature was 
not known. Following the experimental observation of X-ray diffraction in early 1912, 
Max von Laue showed that the wave characteristics of X-ray could be described in terms 
of diffraction from a three-dimensional grating. In the same year, W. L. Bragg noticed the 
similarity of diffraction to ordinary reflection and therefore he deduced a simple equation 




Figure 2.5 Construction showing conditions for diffraction 
 
 Consider an X-ray beam incidents on two parallel planes ( 1P  and 2P ) with inter-
planar spacing of d (Figure 2.5). The parallel incident rays ( 1R  and 2R ) make an angle of 
θ  with these incident planes. Assume that electrons at O and B will be forced to vibrate 
by the oscillating field of the incident beam and they will radiate in all directions as 
vibrating charges. For that particular direction where the parallel secondary rays ( '1R  and 
'2R ) emerge at angle θ  as it reflected from the planes, a diffracted beam of maximum 
intensity will result if the waves represented by these rays are in phase. It can be shown 
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that θ=∠=∠ BOCAOB  by dropping perpendicular from O to A and O to C, 
respectively. Therefore, BCAB = , and waves in ray '2R  will be in phase with those in 
'1R  if BCAB +  is an integral number of wavelengths λ  ( ABBCAB 2=+ ). This can be 
expressed by the equation 
λnAB =2          (2.3) 





AB , (2.3) becomes 
 λθ nd =sin2          (2.4) 
(2.4) is the Bragg’s Law. 





nλ           (2.5) 
When 1=n  
 d2≤λ          (2.6) 
From (2.6), we notice that the radiation used must have wavelengths comparable 




2.3.1 Reciprocal Lattice 





sin λθ =          (2.7) 
It can be seen than θsin  is inversely proportional to the inter-planar spacing in 
the crystal lattice. Since θsin  is a measure of the deviation of the diffracted beam from 
the direct beam, it is evident that crystal structures with large d will exhibit compressed 
diffraction patterns, and conversely for small d. Interpretation of X-ray diffraction 
patterns would be facilitated if the inverse-relation between θsin  and d could be replaced 
by a direct one. This can be achieved by constructing a reciprocal lattice based on d/1 , a 
quantity that varies directly as θsin  (Stout & Jensen, 1968). 
 





cba α= ; 
V





acb β= ; 
V





bac γ= ; 
V
abc γsin* =       (2.10) 
 2/1222 ]coscoscos2coscoscos1[ γβαγβα +−−−= abcV    (2.11) 
 2/1222 *]cos*cos*cos2*cos*cos*cos1[**** γβαγβα +−−−= cbaV  (2.12) 
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2.3.2 Bragg’s Law in Reciprocal Space 
 
Figure 2.6 Diffraction in terms of the reciprocal lattice: 
(a) The reciprocal lattice and the sphere of reflection 
(b) The direct plane (Stout & Jensen, 1968) 
 
Imagine a crystal is placed in an X-ray beam of wavelength, λ . Assume that the 
crystal is oriented in such a way that the X-ray beam lies on the reciprocal lattice ** ca  
plane (Figure 2.6a). The line XO  is in the direction of the beam passing through the 
reciprocal lattice origin O. A sphere of radius λ/1  with its center C on XO and located so 
that O falls on the circumference of the big circle. Consider the properties of a reciprocal 
lattice point P lying on this circle. The angle OPB is inscribed in a semicircle and thus is 




OPOBP ===        (2.13) 
 λθ
2
sin OP=          (2.14) 
Since P is a reciprocal lattice point, the length of OP is by definition equal to hkld/1 . 




sin λθ =          (2.15) 
 λθ =sin2d          (2.16) 
(2.16) is just the Bragg’s Law with n = 1. 
 Generally, this derivation implies that Bragg’s law is fulfilled and reflection 
occurs whenever a reciprocal lattice point coincides with a circle constructed as described. 
The reflecting plane is perpendicular to OP, hence parallel to BP and it makes an angle of 
θ  with OB. The direction of reflection is along OP. The construction is not limited to the 
** ca section but holds for the whole sphere, the sphere of reflection. Thus for any point 
lying on the surface of this sphere, the same conditions hold as for point P in Figure 2.6 
and the conditions for Bragg’s Law reflection are fulfilled for the related direct space 
plane. By rotating the lattice about its origin, various reciprocal lattice points can be 
brought into coincidence with the surface of sphere of reflection and the corresponding 
reflection can be observed. 
 
 
Figure 2.7 Sections through the sphere of reflection and the limiting sphere: 
(a) for reciprocal lattice defined as d/1  
(b) for reciprocal lattice defined as d/λ  (Stout & Jensen, 1968) 
